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HIV-1 adaptation to NK-cell-mediated immune
pressure
Galit Alter1*, David Heckerman2*, Arne Schneidewind1*, Lena Fadda1*, Carl M. Kadie2, Jonathan M. Carlson2,
Cesar Oniangue-Ndza1, Maureen Martin3, Bin Li1, Salim I. Khakoo4, Mary Carrington1,3, Todd M. Allen1 & Marcus Altfeld1
Natural killer (NK) cells have an important role in the control of
viral infections, recognizing virally infected cells through a variety
of activating and inhibitory receptors1–3. Epidemiological and
functional studies have recently suggested that NK cells can also
contribute to the control of HIV-1 infection through recognition
of virally infected cells by both activating and inhibitory killer
immunoglobulin-like receptors (KIRs)4–7. However, it remains
unknown whether NK cells can directly mediate antiviral immune
pressure in vivo in humans. Here we describe KIR-associated
amino-acid polymorphisms in the HIV-1 sequence of chronically
infected individuals, on a population level. We show that these
KIR-associated HIV-1 sequence polymorphisms can enhance the
binding of inhibitory KIRs to HIV-1-infected CD41 T cells, and
reduce the antiviral activity of KIR-positive NK cells. These data
demonstrate that KIR-positive NK cells can place immunological
pressure on HIV-1, and that the virus can evade such NK-cell-
mediated immune pressure by selecting for sequence polymorph-
isms, as was previously described for virus-specific T cells and
neutralizing antibodies8. NK cells might therefore have a previ-
ously underappreciated role in contributing to viral evolution.
We hypothesized that HIV-1 can evade recognition by NK cells
through the selection of sequence polymorphisms in regions targeted
by KIRs, and that KIR-associated polymorphisms in the HIV-1
sequence can be identified on a population level. To test this hypothesis,
we examined the relationship between KIR genotypes andHIV-1 poly-
morphisms in a cohort of 91 untreated, chronically HIV-1-infected
individuals (Supplementary Table 1), in whom full-length HIV-1
sequences were determined and HLA-class-I-associated polymorph-
ismswere previously described9.We used a decision-tree approach that
corrects for phylogenetic structure among the sequences and allows for
a multivariate analysis to identify KIR-associated sequence poly-
morphisms10. This analysis led to the identification of 22 positions in
the HIV-1 genome at which amino-acid polymorphisms were signifi-
cantly associated with the presence of a specific KIR gene (Table 1 and
Supplementary Fig. 1). Taken together, these data show thatHIV-1 can
adapt to host KIR genotypes on a population level.
To assess the consequences of these KIR-associated amino-acid
polymorphisms forNK-cell-mediated recognition of cells infectedwith
HIV-1, we initially evaluated polymorphisms in a region of HIV-1 that
encodes an overlapping segment that spans the carboxy-terminal end
of Vpu and the amino-terminal end of Env (polymorphisms 15–18 in
Table 1 and Supplementary Fig. 1). We selected this region because
these polymorphisms were present in both reading frames at signifi-
cantly higher frequencies in individuals that possessed at least one copy
of the KIR2DL2 gene than in individuals that did not (Table 2 and
Supplementary Tables 2 and 3). In amino-acid positions 71 and 74 of
Vpu, HIV-1 sequences derived from KIR2DL2-positive individuals
encoded a methionine in position Vpu(71) and a histidine in position
Vpu(74) in more than 70% of cases. Because of the overlapping Vpu/
Env coding region, these positions of Vpu corresponded to a trypto-
phan in position Env(17) and a methionine in position Env(20),
respectively. The Vpu(71M/74H) (Env(17W/20M)) sequence was sig-
nificantly less frequent in HIV-1-infected individuals that did not
encode KIR2DL2 (P, 0.0001). Furthermore, the presence of the
Vpu(71M) polymorphism was in strong linkage disequilibrium with
the Vpu(74H) polymorphism (P5 3.17212). Taken together, these
data demonstrate a significant enrichment ofHIV-1 viruses containing
the Vpu(71M/74H) (Env(17W/20M)) polymorphism in individuals
encoding KIR2DL2.
To determine the functional consequences of these KIR2DL2-assoc-
iated polymorphisms in Vpu and Env, we constructed HIV-1 viral
variants using the backbone of the HIV-1 NL4-3 strain11,12. These var-
iants encoded either the Vpu(71M/74H) (Env(17W/20M)) sequence
that was seen in KIR2DL21 individuals (referred to as Vpu–EnvV/V,
with ‘V’ standing for variant), or the Vpu(71R/74L) (Env(17G/20L))
sequence that was most commonly seen in KIR2DL22 subjects
(referred to as Vpu–EnvWT/WT). No significant differences were
observed in the ability of the viral variants to replicate in primary
CD41 T cells in vitro (Supplementary Fig. 2a). We subsequently
assessed whether the different viral variants had any impact on NK-
cell recognition and/or antiviral activity. Primary CD41 T cells were
infected with viruses containing either the Vpu–EnvV/V or the Vpu–
EnvWT/WT sequence, and thenplaced in co-culturewith autologousNK
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Table 1 | KIR footprints in HIV-1 sequence
Protein Amino-acid
position
KIR association Consensus
amino acid*
Q value
1 Gag 93 KIR2DS3 E 0.1389
2 Gag 138 KIR2DL2 L 0.1852
3 Gag 138 KIR2DS2 L 0.1852
4 Gag 371 KIR2DS5 T 0
5 Gag 389 KIR3DS1 T 0
6 Gag 479 KIR2DS1 I 0
7 Vpr 37 KIR2DS3 I 0.0909
8 Tat 3 KIR2DL2 S 0.0246
9 Tat 3 KIR2DS2 S 0
10 Tat 3 KIR3DS1 S 0.1311
11 Tat 9 KIR2DS3 P 0.1311
12 Tat 28 KIR2DS1 V 0.1311
13 Tat 28 KIR2DS5 V 0.1339
14 Vpu 3 KIR2DL3 S 0.0833
15 Vpu 71 KIR2DL2 M 0.125
16 Vpu 74 KIR2DL2 H 0.1354
17 Env 17 KIR2DL2 W 0
18 Env 20 KIR2DL2 M 0.1667
19 Env 46 KIR3DS1 K 0.1667
20 Env 347 KIR2DS1 L 0.2
21 Env 595 KIR2DS1 I 0.2
22 Nef 9 KIR2DL2 S 0.0833
*HIV-1 consensus sequence in the 91 study subjects.
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cells derived from KIR2DL21 or KIR2DL22 HIV-1-negative indivi-
duals (Fig. 1). Both viruses replicatedwell in the presence ofKIR2DL22
NK cells, with less than half a log inhibition of viral replication in the
presence of NK cells compared to replication in CD41 T cells alone
(Fig. 1a, b). In contrast, the Vpu–EnvWT/WT virus was markedly
inhibited by NK cells derived from KIR2DL21, but not KIR2DL22,
subjects (Fig. 1b). Thus, the Vpu–EnvV/V virus, which contains poly-
morphisms that were strongly associated with the presence of KIR2DL2
on thepopulation level,wasnot inhibitedbyKIR2DL21NKcells in vitro,
whereas the ‘wild-type’ variant that was rarely observed in KIR2DL21
individuals was strongly inhibited by KIR2DL21 NK cells, consistent
with the selection of Vpu–EnvV/V viruses in KIR2DL21 individuals.
To elucidate further the mechanism by which KIR2DL21 NK cells
inhibit replication of Vpu–EnvWT/WT viruses, we monitored the
induction of CD107a expression on NK cells in vitro after stimulation
with autologous CD41T cells infected with either the Vpu–EnvWT/WT
Table 2 | Frequency of amino-acid polymorphisms among KIR2DL21 and KIR2DL22 subjects
KIR2DL2 status Vpu (amino-acid position) Percentage of individuals Number of individuals
E (70) M (71) G (72) H (73) H (74) A (75) P (76) W (77) D (78) V (79)
KIR2DL21 ?/P/D ? ? ? ? ? ? ? N/? I/? 72 (34/47)
? L/Q/-/? ? ? D/L/? ? ? ? ? I/? 24 (11/47)
? R ? ? L ? ? ? ? I/? 4 (2/47)
KIR2DL22 ?/D ? ?/E ?/Q ? ?/D ? ? ? ? 32 (14/44)
?/H/M N/V/Q/G ?/A ? D/R ? ?/L ?/G ?/V ?/I 34 (15/44)
?/H R ? ?/R L ? ?/L ?/G/R/L ?/V ?/I 34 (15/44)
KIR2DL2 status Env (amino-acid position) Percentage of individuals Number of individuals
R (16) W
(17)
G
(18)
T
(19)
M
(20)
L
(21)
L
(22)
G
(23)
M
(24)
L (25)
KIR2DL21 ?/K ? ? ?/I ? ? ? ? ?/L/I ? 85 (40/47)
?/K R/? ? I T/? ? ? ? ? ? 11 (5/47)
?/K G ? I/A L ?/F ? ? ?/I ? 4 (2/47)
KIR2DL22 ?/K ? ? ?/I ? ? ? ? ?/I ? 43 (19/44)
? R/M ? ?/I ?/V ? ? ? ?/I ? 23 (10/44)
?/K G ? ?/I L ? ? ? ?/I ? 34 (15/44)
KIR2DL2 status Gag (amino-acid position) Percentage of individuals Number of individuals
I (134) V
(135)
Q
(136)
N
(137)
L
(138)
Q
(139)
G
(140)
Q
(141)
M
(142)
V (143)
KIR2DL21 ? ? ? ? ? ? ? ? ? ?/I 68 (32/47)
?/V ? ? ? M/V/A ? ? ? ? ?/I 32 (15/47)
? ? ? ? I ? ? ? ? ? 0 (0/47)
KIR2DL22 ? ? ?/R ? ? ? ? ? ? ? 57 (25/44)
? ? ?/R ? M/V/A ? ? ? ? ? 25 (11/44)
? ? ? ? I ? ? ? ? ? 18 (8/44)
KIR2DL2 status Nef (amino-acid position) Percentage of individuals Number of individuals
W (5) S
(6)
K
(7)
R
(8)
S
(9)
V
(10)
V
(11)
G
(12)
W
(13)
P (14)
KIR2DL21 ?/X ? ? ?/X ? ?/X ?/X ?/X ? ?/X 75 (35/47)
?/X ? ? ?/X E/R/N/C/L/- ?/X ?/X ?/E ? ?/X 23 (11/47)
? ? ? ? K E N ? ? S 2 (1/47)
KIR2DL22 ?/C ? ?/R ?/X ? ?/X ?/X ?/X ? ?/X 52 (23/44)
?/C ? ?/R ?/X -/P/R/I/G/W ?/X ?/X ?/X ? ?/X 27 (12/44)
? ? ? ?/X K ?/X ?/X ?/D ? ?/S 21 (9/44)
The KIR2DL2-associated sequence polymorphisms in Vpu, Env, Gag andNef are highlighted in bold. The consensus sequence in the 91 studied individuals is listed in the respective headings. Themost common
amino acid substitutions are shown for the respective positions. X, positions in which several different amino acids were observed; -, amino-acid deletions; ?, identical amino acids as in consensus sequence.
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Figure 1 | KIR2DL2-associated sequence polymorphisms result in a loss of
inhibition of HIV replication by NK cells in vitro. a, The Vpu–EnvWT/WT
virus was inhibited more robustly than the Vpu–EnvV/V virus by NK cells
derived from a KIR2DL21 individual (grey lines). NK cells derived from a
KIR2DL22 individual (black lines) did not inhibit either virus. b, The Vpu–
EnvWT/WT virus (dark grey bars) was inhibited significantlymore strongly than
the Vpu–EnvV/V virus (black bars) by NK cells derived from individuals that
expressed KIR2DL2 (n5 6). NK cells derived from individuals that did not
express KIR2DL2 (white bars, n5 6) did not significantly inhibit either virus.
*, P, 0.05; **, P, 0.005;1, KIR2DL2-positive;2, KIR2DL2-negative. All
results are given as mean and s.e.m.
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or the Vpu–EnvV/V virus (Fig. 2a–c). Consistent with the viral inhibi-
tion data, CD158b1 NK cells from KIR2DL21 individuals were
strongly activated by CD41 T cells infected with the Vpu–
EnvWT/WT virus, but not by CD41 T cells infected with the Vpu–
EnvV/V virus (Fig. 2a–c). These data are consistent with a model in
which the inhibitory NK-cell receptor KIR2DL2 does not bind to cells
infected with HIV-1 strains containing the Vpu–EnvWT/WT sequence,
but can bind to cells infected with HIV-1 Vpu–EnvV/V, providing a
strong inhibitory signal to KIR2DL21NK cells and thereby protecting
cells infected with Vpu–EnvV/V viruses from lysis by NK cells.
KIR2DL2 segregates with KIR2DL3, as an allele of the same locus13,
and is in strong linkage disequilibrium with KIR2DS2 (Wn, weighted
normalized statistic for linkage disequilibrium 5 0.976, P, 0.001),
therefore most individuals in our cohort expressed both these KIRs.
However, the three individuals in our cohort who expressed KIR2DL2
in the absence ofKIR2DS2also encoded theVpu(71M)polymorphism,
indicating that KIR2DL2, not KIR2DS2, is responsible for the asso-
ciationwith this polymorphism. To test whetherKIR2DL2was directly
involved in the recognition of the viral variants, a KIR2DL2–IgG fusion
construct was used to assess whether the Vpu–EnvV/V polymorphism
modulated the interaction of KIR2DL2 with HIV-1-infected CD41
T cells. The KIR2DL2 fusion construct bound robustly to all uninfected
CD41 T cells, and also bound to CD41 T cells infected with the HIV-1
Vpu–EnvV/V variant significantly better than to CD41 T cells from the
same donor infected with the Vpu–EnvWT/WT variant (Fig. 2d–f). In
contrast, the binding of a KIR2DL3 fusion construct toHIV-1-infected
CD41T cells was not significantly affected by the KIR2DL2-associated
polymorphism (Fig. 2e, f). HLA-C group 1 and group 2molecules serve
as the ligands for the inhibitory receptor KIR2DL2, which has been
shown to bind with greater affinity to HLA-C group 1 than group 2
(ref. 13). Staining with the KIR2DL2 fusion construct was consistent
with these results, because it bound most strongly to cells from indivi-
duals homozygous for HLA-C group 1 (Supplementary Fig. 3). Con-
sistent with these binding data, the Vpu–EnvV/V polymorphisms were
significantly enriched inKIR2DL21 individuals homozygous forHLA-
C group 1 (P5 0.008 for Vpu(71M) and P5 0.01 for Vpu(74H)).
Taken together, these data indicate that the Vpu–EnvV/V polymorph-
ism enhances the ability of the inhibitory receptor KIR2DL2 to bind to
HIV-1-infected cells, in particular those expressing the ligands with
highest affinity for KIR2DL2.
In addition to the Vpu(71M/74H) polymorphism, two additional
amino-acid polymorphisms (Gag(138L/I) and Nef(9S/K)) were asso-
ciated with the presence of the KIR2DL2 gene in the study population
(Table 1, polymorphisms 2 and 22). We next determined whether
these KIR2DL2-associated polymorphisms were also associated with
differential recognition of HIV-1-infected cells by KIR2DL21 NK
cells. Viruses containing the polymorphisms replicated similarly in
CD41 T cells (Supplementary Fig. 2b). As observed for the Vpu and
Env variants, viruses containing the amino acids that were rarely
observed in KIR2DL21 individuals (GagWT and NefWT, Table 2 and
Supplementary Tables 4 and 5) were inhibited more strongly by NK
cells derived fromKIR2DL21 individuals thanwere viruses containing
the variants selected in KIR2DL21 subjects (Fig. 3a, c). Furthermore,
KIR2DL21NK cells degranulatedmore robustly in response to CD41
T cells infected with the GagWT and NefWT viruses (Fig. 3b, d), and
KIR2DL2–IgG fusion constructs bound significantly less to CD41
T cells infected with the GagWT and NefWT viruses than to cells
infected with GagV and NefV viruses (Fig. 4a–c). Taken together, these
data demonstrate that HIV-1 may evolve in KIR2DL21 individuals to
enrich particular amino-acid polymorphisms, in an effort to escape
recognition by KIR2DL21 NK cells.
Increasing amounts of evidence indicate that NK cells have an
important role in the control of HIV-1 infection4–6. Here we report
several amino-acid polymorphismswithin theHIV-1 clade B sequence
that are significantly associated with the expression of specific KIR
genes on the population level. We demonstrate in functional studies
that these ‘KIR footprints’ can modulate the interaction of KIR1 NK
cells with HIV-1-infected CD41 T cells. The selection of particular
c
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Figure 2 | Amino-acid polymorphisms at positions 71 and74 inVpu inhibit
KIR2DL2, but not KIR2DL3, recognition and binding. a, Flow cytometric
plots depicting the percentages of total CD158b(KIR2DL2/2DL3/2DS2)1 NK
cells that degranulated after co-culture with autologous CD41 T cells infected
with the Vpu–EnvWT/WT virus or the Vpu–EnvV/V virus for two representative
subjects (left panels, KIR2DL21 subjects; right panels, KIR2DL22 subjects).
b, The percentage of degranulating CD1581NK cells in the total CD1581NK-
cell population is also represented in histograms for both the KIR2DL21 donor
(left panel) and KIR2DL22 donor (right panel), for both the WT/WT virus
(black line) and the V/V virus (grey line). c, Combined data for NK-cell
degranulation in KIR2DL21 (n5 5) and KIR2DL22 (n5 5) individuals.
*, P, 0.05. d, Staining pattern of a KIR2DL2–IgG fusion construct on HIV-
infected CD41 T cells from an HLA-C1/C2 heterozygous donor. Percentages
indicate the percentage of p242 or p241 cells that were stained with the
KIR2DL2–IgG fusion construct. e, Staining of KIR2DL2–IgG and KIR2DL3–
IgG fusion constructs on the same donors infected with the WT/WT and V/V
viral variants. f, Summary of binding data for the KIR2DL2–IgG (black) and
KIR2DL3–IgG (grey) fusion constructs for five differentHLA-C1heterozygous
CD41 T-cell donors after infection with the two viral variants. **, P, 0.005.
All results are given as mean and s.e.m.
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amino-acid residues that result in enhanced binding of inhibitoryKIRs
to infected cells represents a novel approach bywhichHIV-1 can evade
NK-cell-mediated immunity. The molecular mechanisms and precise
receptor–ligand interactions involved in this evasion of NK-cell
recognition require further investigation. Previous in vitro studies have
demonstrated that sequence variations in HLA-class-I-presented
epitopes14–23 and small changes in the peptide repertoire presented
on HLA class I molecules24 can both modulate the binding of KIR,
providing a potential mechanism for virus-sequence-dependent
recognition of infected cells by NK cells. The KIR2DL2-associated
sequence polymorphisms studied here had no impact on KIR2DL2
binding to transporter associated with antigen processing (TAP)-
deficient T2 cells expressing HLA-Cw*0102 (Supplementary Fig. 4),
despite some degree of HLA-Cw*0102 stabilization. However, several
different HLA-C group 1 molecules might present epitopes in these
regions of HIV-1, resulting in differential recognition by KIR2DL2.
Additionally, othermechanisms besides themodulationofKIR binding
to HLA class I might account for the observed reduction in recognition
of variant-virus-infected cells by KIR2DL21 NK cells. KIR-associated
sequence polymorphisms in HIV-1 proteins might directly modulate
the ability of these proteins to be processed and presented25, might
subtly alter hydrostatic interactions with KIR, or might change the
profile of NK-cell receptor ligands expressed on infected cells, as has
been described for HIV-1 Nef, Vpu and Vpr26,27.
Protective effects of specific KIRs or combinations of KIR and HLA
class I have been described for many infectious diseases, including
HIV, hepatitis C virus and human papilloma virus. Although
KIR2DL2 has not been identified as a protective KIR gene in any of
these viral infections, homozygosity of its allotypic counterpart,
KIR2DL3, has been associated with the resolution of hepatitis C infec-
tion when KIR2DL3 is co-expressed with its ligand, HLA-C group 1
(ref. 28). This protective KIR2DL3/HLA-C group 1 combination pro-
vides a weaker inhibitory signal, resulting in weaker inhibition of NK
cells28. Here we describe a mechanism by which HIV-1 selects for
sequence polymorphisms in KIR2DL21 individuals that lead to an
enhanced binding of this inhibitory KIR to infected cells, resulting in
the inhibition of NK-cell function and thereby enabling HIV-1 to
escape the potential protective role of this KIR. Overall, the data from
different viral infections are consistent with a model in which
enhanced NK-cell activity can contribute to the control of viral rep-
lication, and indicate that viruses can evade this NK-cell-mediated
immune pressure by selecting for variants that modulate the recog-
nition of infected cells by KIR.
METHODS SUMMARY
Viral sequencing. Genomic DNA was extracted from samples of peripheral blood
mononuclear cells and nested PCRprotocols were used to amplifyHIV-1 genomes9.
Phylogenetic analysis of KIR-associated sequence polymorphisms.Adecision-
tree approach10, followed by adjustment for multiple comparisons, was used to
identify KIR-associated sequence polymorphisms.
Construction of viruses containing sequence polymorphisms. Mutations of
interest were inserted into the HIV-1 NL4-3 backbone using the GeneTailor
site-directed mutagenesis system11,12.
Viral inhibition assay. Viral inhibition assays were performed after infecting
CD41 T cells with viral constructs, as indicated. The level of viral inhibition was
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Figure 3 | Two additional KIR2DL2-associated amino-acid polymorphisms
reduce KIR2DL2-mediated NK-cell recognition of virally infected cells.
a, c, NK cells from KIR2DL21 individuals (n5 5) inhibited the replication of
theNef-WTvirus and theGag-WTvirus significantly better than they inhibited
replication of the Nef-V and Gag-V viruses. b, d, NK cells derived from
KIR2DL21 individuals (n5 5) were activated significantly more by cells
infected with the Nef-WT andGag-WT viruses than by cells infected with Nef-
V and Gag-V viruses. However, NK cells derived from KIR2DL22 individuals
(n 5 3) did not inhibit viral replication or degranulate in response to cells
infected with either of the wild-type or variant viruses. *, P, 0.05. All results
are given as mean and s.e.m.
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Figure 4 | KIR2DL2-associated amino-acid polymorphisms affect binding
of KIR2DL2, but not KIR2DL3, to infected CD41 T cells. CD41 T cells
infectedwithvariant viruseswere stainedwithKIR2DL2–IgGandKIR2DL3–IgG
fusion constructs. a, b, The dot plots (a) and histograms (b) show the staining
pattern of KIR2DL2–IgG and KIR2DL3–IgG fusion constructs on HIV-1-
infected CD41 T cells from aHLA-C1/C2 heterozygous donor. c, The bar graph
summarizes binding data for KIR2DL2 (black) or KIR2DL3 (grey) IgG fusion
constructs for five different HLA-C1/C2 heterozygous CD41 T-cell donors
infectedwith viral variants. **, P, 0.005.All results are given asmean and s.e.m.
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then calculated as the difference between viral production (p24 Gag) in wells con-
taining autologousNKcells and production inwells containingCD41Tcells alone6.
NK-cell degranulation assay.Degranulation ofKIR2DL21NKcellswas examined
by flow cytometry after co-culture ofNKcells with autologousCD41Tcells infected
with the viral construct indicated, in the presence of Golgi-stop and anti-CD107a-
PECy5 for 6 h (ref. 29). NK cells were stained with anti-CD3, anti-CD56, anti-CD16
and anti-CD158b (KIR2DL2/2DL3/2DS2) antibodies, and the level of degranulation
was assessed as the proportion of CD107a1NKcells among the CD158b1NKcells.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
Received 14 December 2009; accepted 31 May 2011.
1. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition.Nature
Immunol. 9, 495–502 (2008).
2. Yokoyama, W. M. Specific and non-specific natural killer cell responses to viral
infection. Adv. Exp. Med. Biol. 560, 57–61 (2005).
3. Lanier, L. L. NK cell recognition. Annu Rev Immunol 23, 225–274 (2004).
4. Martin, M. P. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the
progression to AIDS. Nature Genet. 31, 429–434 (2002).
5. Martin,M. P.et al. Innatepartnership ofHLA-B andKIR3DL1 subtypes againstHIV-
1. Nature Genet. 39, 733–740 (2007).
6. Alter, G. et al.Differential natural killer cell mediated inhibition of HIV-1 replication
based on distinct KIR/HLA subtypes. J. Exp. Med. 204, 3027–3036 (2007).
7. Altfeld, M. & Goulder, P. ‘Unleashed’ natural killers hinder HIV. Nature Genet. 39,
708–710 (2007).
8. Goulder, P. J. & Watkins, D. I. HIV and SIV CTL escape: implications for vaccine
design. Nature Rev. Immunol. 4, 630–640 (2004).
9. Wang, Y. E. et al.ProtectiveHLA class I alleles that restrict acute-phase CD81 T-cell
responses are associated with viral escapemutations located in highly conserved
regions of human immunodeficiency virus type 1. J. Virol. 83, 1845–1855 (2009).
10. Carlson, J. M. et al. Phylogenetic dependency networks: inferring patterns of CTL
escape and codon covariation in HIV-1 Gag. PLOS Comput. Biol. 4, e1000225
(2008).
11. Schneidewind, A. et al. Escape from the dominant HLA-B27-restricted cytotoxic
T-lymphocyte response in Gag is associated with a dramatic reduction in human
immunodeficiency virus type 1 replication. J. Virol. 81, 12382–12393 (2007).
12. Adachi, A. et al. Production of acquired immunodeficiency syndrome-associated
retrovirus in human andnonhuman cells transfectedwith an infectiousmolecular
clone. J. Virol. 59, 284–291 (1986).
13. Moesta, A. K. et al. Synergistic polymorphism at two positions distal to the ligand-
binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
J. Immunol. 180, 3969–3979 (2008).
14. Stewart, C. A. et al. Recognition of peptide-MHC class I complexes by activating
killer immunoglobulin-like receptors.Proc.Natl Acad. Sci.USA102,13224–13229
(2005).
15. Stewart-Jones, G. B. et al. Crystal structures and KIR3DL1 recognition of three
immunodominant viral peptides complexed to HLA-B*2705. Eur. J. Immunol. 35,
341–351 (2005).
16. Boyington, J. C.,Motyka, S. A., Schuck, P., Brooks, A.G.&Sun,P. D. Crystal structure
of anNK cell immunoglobulin-like receptor in complex with its class I MHC ligand.
Nature 405, 537–543 (2000).
17. Thananchai, H. et al. Cutting edge: allele-specific and peptide-dependent
interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178, 33–37
(2007).
18. Rajagopalan, S. & Long, E. O. The direct binding of a p58 killer cell inhibitory
receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits
peptide selectivity. J. Exp. Med. 185, 1523–1528 (1997).
19. Malnati, M. S. et al. Peptide specificity in the recognition of MHC class I by natural
killer cell clones. Science 267, 1016–1018 (1995).
20. Peruzzi, M., Parker, K. C., Long, E. O. & Malnati, M. S. Peptide sequence
requirements for the recognition of HLA-B*2705 by specific natural killer cells.
J. Immunol. 157, 3350–3356 (1996).
21. Mandelboim, O., Wilson, S. B., Vales-Gomez, M., Reyburn, H. T. & Strominger, J. L.
Self and viral peptides can initiate lysis by autologous natural killer cells. Proc. Natl
Acad. Sci. USA 94, 4604–4609 (1997).
22. Mandelboim, O. et al. The binding site of NK receptors on HLA-C molecules.
Immunity 6, 341–350 (1997).
23. Fadda, L. et al. Common HIV-1 peptide variants mediate differential binding of
KIR3DL1 to HLA-Bw4 molecules. J. Virol. 85, 5970–5974 (2011).
24. Fadda, L. et al. Peptide antagonism as a mechanism for NK cell activation. Proc.
Natl Acad. Sci. USA 107, 10160–10165 (2010).
25. LeGall, S., Stamegna, P.&Walker, B.D. Portable flanking sequencesmodulate CTL
epitope processing. J. Clin. Invest. 117, 3563–3575 (2007).
26. Ward, J. et al. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells
through activation of the ATR-mediated DNA damage response. PLoS Pathog. 5,
e1000613 (2009).
27. Ward, J. et al. HIV modulates the expression of ligands important in triggering
natural killer cell cytotoxic responses on infected primary T-cell blasts.Blood 110,
1207–1214 (2007).
28. Khakoo, S. I.et al.HLAandNKcell inhibitory receptor genes in resolvinghepatitis C
virus infection. Science 305, 872–874 (2004).
29. Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the
identification of natural killer cell activity. J. Immunol. Methods 294,15–22 (2004).
Supplementary Information is linked to the online version of the paper at
www.nature.com/nature.
Acknowledgements These studies were supported by National Institutes of Health
(NIH)/National Institute of Allergy and InfectiousDiseases grants R01AI067031 (M.A.)
and PO1 AI074415 (M.A. and T.M.A.), and by the Doris Duke Charitable Foundation
(M.A.). This project was funded in whole or in part with federal funds from the National
Cancer Institute (NIH) under contract HHSN261200800001E. The content of this
publication does not necessarily reflect the views or policies of the Department of
HealthandHumanServices, nordoesmentionof tradenames, commercial productsor
organizations imply endorsement by theUSgovernment. This researchwas supported
in part by the Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research. S.I.K. is a recipient of a Wellcome Trust Senior Clinical
Fellowship and M.A. is a Distinguished Clinical Scientist of the Doris Duke Charitable
Foundation. We thank Microsoft Research, the Bill & Melinda Gates Foundation, the
Mark and Lisa Schwartz Foundation and the Phillip T. andSusanM. Ragon Foundation
for their support.
Author Contributions G.A. conducted the immunology experiments and L.F.
performed the KIR-staining experiments on T2 cell lines. A.S. and C.O.-N. constructed
the viral variants. D.H., C.M.K. and J.M.C. performed the data analysis identifying
KIR-associated polymorphisms. B.L. and T.M.A. performed the viral sequencing, M.C.
andM.M. performed theHLA and KIR typing, and L.F. and S.I.K. provided the KIR fusion
construct. G.A. andM.A. planned the studies, prepared themanuscript and supervised
the project.
Author Information Reprints and permissions information is available at
www.nature.com/reprints. The authors declare no competing financial interests.
Readers are welcome to comment on the online version of this article at
www.nature.com/nature. Correspondence and requests for materials should be
addressed to M.A. (maltfeld@partners.org).
RESEARCH LETTER
1 0 0 | N A T U R E | V O L 4 7 6 | 4 A U G U S T 2 0 1 1
Macmillan Publishers Limited. All rights reserved©2011
METHODS
Study subjects. Ninety-one untreated subjects chronically infected with HIV-1
subtype B, for which HLA class I and KIR genotypes were available (Supplemen-
tary Table 1), were included in this study9. In addition, 100 HIV-1 negative
controls were genotyped for KIR and HLA genotypes. Of this large cohort of
uninfected controls, 15 subjects that were KIR2DL21 (KIR2DL21/KIR2DL31)
and 15 subjects that were KIR2DL22 (KIR2DL31/KIR2DL31) were enrolled to
provide samples for the generation of NK cells and autologous CD41 target cells
(Supplementary Table 6). For these in vitro studies, only individuals that did not
encode KIR3DS1 and HLA-B Bw4-80I were selected, because we had previously
observed very strong inhibition of HIV-1 replication in vitro in individuals with
this combined KIR/HLA genotype6. All study subjects were enrolled in Boston
through the Massachusetts General Hospital, the Lemuel-Shattuck Hospital and
the Fenway Community Health Center. The study was approved by the
Massachusetts General Hospital Review Board and all subjects gave written
informed consent.
Viral sequencing. Genomic DNA was extracted from peripheral blood mononuc-
lear cell samples and nested PCR protocols were used to amplify HIV-1 genomes as
described previously9. Five independent PCR products of each sample were pooled
and directly population-sequenced at the Massachusetts General Hospital DNA
sequencing core facility using clade B consensus sequencing primers, as previously
described9.
HLA class I and KIR typing.High-resolution HLA class I typing and KIR geno-
typing were performed as described previously6.
Phylogenetic analysis of KIR-associated sequence polymorphisms. We used
the decision-tree approach10, which corrects for phylogenetic structure among the
sequences and allows for a multivariate analysis, to identify KIR-associated
sequence polymorphisms. All results were adjusted for multiple comparisons
(both P and Q values are assigned to each result). For each protein analysed, a
maximum likelihood phylogenetic tree was constructed from the corresponding
sequences. For every KIR and HLA gene, amino-acid position and amino acid at
that position, we created two generative or directed graphical models of the
observed presence or absence of the amino acid in each sequence: one representing
the null hypothesis that the observations are generated by the phylogenetic tree
alone and the other representing the alternative hypothesis that additional escape
or reversion takes place owing to KIR/HLA pressure in the subjects for which the
sequences are observed. The likelihood of the observations was then maximized
over the parameters of both models using an expectation-maximization algorithm,
and aP valuewas computedusing a likelihood ratio test basedon those likelihoods10.
To increase power, the tests were binarized, such that the presence or absence of a
givenKIRorHLAgenewas correlatedwith the presence or absenceof a given amino
acid. In addition, KIR–polymorphism pairs were analysed only when the actual or
expected count in every cell of the corresponding two-by-two contingency table was
$3. For every amino acid at each position, the KIR or HLA gene with the strongest
association (and its corresponding P value) was added to the list of identified
associations. The analysis was then repeated after removing individuals having
or possibly having this KIR orHLA gene. This procedurewas iterated until noKIR
or HLA gene yielded an association with a P value less than 0.05. A Q-value
statistic, estimating the proportion of false positives among the associations iden-
tified, was computed for each association by repeating this analysis on null data
(generated bypermuting theKIR/HLAdata).Correction formultiple comparisons
was undertaken using both Q, 0.05 (estimating 5% false positives) and Q, 0.2
(estimating 20% false positives).
Construction of viruses containing sequence polymorphisms. The HIV-1
strain NL4-3 was modified to express one or two mutations in vpu/env, nef or
gag using the GeneTailor site-directed mutagenesis system (Invitrogen) or the
QuikChange Lightning site-directed mutagenesis system (Stratagene)11,12. In brief,
mutagenesis was performed using 59 oligonucleotide primers Vpu_M71R-f
(CTTGTGGAGATGGGGGTGGAAAGGGGGCACCAT (nucleotide (nt) 6279)),
Vpu_M71R-r (TTTCCACCCCCATCTCCACAAGTGCTGATACTTCT (nt 6234)),
Vpu_H74L-f (ATGGGGGTGGAAATGGGGCACCTTGCTCCTTGG), Vpu_H74L-r
(GGTGCCCCATTTCCACCCCCATCTCCACAAG (nt 6247)), Vpu_M71R/H74L-f
(ATGGGGGTGGAAAGGGGGCACCTTGCTCCTTGG (nt 6247 and nt 6288))
and Vpu_M71R/H74L-r (GGTGCCCCCTTTCCACCCCCATCTCCACAAG
(nt 6247)); Nef/S9K-f (GTGGTCAAAAAGTAAAGTGATTGGATGGCC (nt 8827))
and Nef/S9K-r (GGCCATCCAATCACTTTACTTTTTGACCAC (nt 8798));
Gag/L138I-f (CCTATAGTGCAGAACATCCAGGGGCAAATGG (nt 1216)) and
Gag/L138I-r (CCATTTGCCCCTGGATGTTCTGCACTATAGG (nt 1186)).
Mutated nucleotides are underlined andprimer positions are numbered according
to the numbering of NL4-3 (GenBank accession number AF324493). The com-
pleteHIV-1 coding region of the variant proviruses was sequenced on anABI3730
XL DNA analyser. Propagation of provirus and generation of viral stocks was
performed as previously described11,12. Although the full-length sequence of the
NL4-3 viruses differed from the autologous sequence of the respective study sub-
jects, the areas flanking the vpu, gag and nef sequences studied were identical
between the NL4-3 virus and the respective areas of interest, and only differed
in the amino acids indicated in Supplementary Tables 2–5.
Viral inhibition assay. Viral inhibition assays using NK cells were performed as
previously described6. CD41Tcells thatwere generated after 4 days in culturewith
a bi-specific antibody to CD3 and CD8 were infected with laboratory strains
containing amino-acid polymorphisms at a multiplicity of infection of 0.01 for
4 h at 37 uC. Cells were washed twice. Equal numbers of CD41 T cells were plated
at NK-cell/CD41 T cell ratios of 10:1, or alone, for 14 days in the presence of
50Uml21 interleukin-2. Supernatant was collected every 3–4 days for quantifica-
tion of p24 Gag production by enzyme-linked immunosorbent assay (p24 ELISA;
Perkin Elmer).
NK-cell degranulation assay.ToexaminewhetherKIR2DL21NKcells specifically
degranulated in response to autologous CD41 T cells infected with either of the
viral variants, we monitored the level of CD107a upregulation on KIR2DL21 or
KIR2DL22 NK cells29. We selected HIV-1-negative donors that expressed
KIR2DL2 in the absence of KIR2DS2 (referred to as KIR2DL21), or KIR2DL3
in the absence of KIR2DL2 and KIR2DS2 (referred to as KIR2DL22). An anti-
CD158b antibody was used to detect NK cells expressing KIR2DL2, KIR2DL3 and
KIR2DS2. The level of degranulation was assessed as the proportion of CD107a1
NK cells among the CD158b1NK cells. NK cells thus purified were co-cultured in
the presence of autologousCD41Tcells infected in vitrowith the respectiveHIV-1
strains for 7 days. Monensin was added to co-cultures on day 7 at 0.3mgml21, in
the presence of 20ml CD107a-PE-Cy5, for 6 h. Cells were washed and stained with
CD3-Pacific Blue, CD56-PE-Cy7, CD16-APC-Cy7 (BD Biosciences) and
CD158b-PE (Beckman Coulter) for 30min, then washed and fixed in 1% para-
formaldehyde until flow cytometric analysis was performed (FACSCalibur; BD
Biosciences).
KIR–IgG fusion construct binding assay.Differences in the ability of KIR2DL2
or KIR2DL3 to interact with CD41 T cells infected with either of the viral variants
were ascertained using KIR2DL2–IgG and KIR2DL3–IgG fusion constructs (pro-
vided by S. Khakoo and O. Mandelboim). Peripheral blood mononuclear cells
were obtained from HLA-C1/C1 homozygotes, HLA-C1/C2 heterozygotes or
HLA-C2/C2 homozygotes, and were treated with 0.3mg of a bispecific CD3/
CD8 antibody in the presence of 50U interleukin-2 per ml of complete medium.
After 3 days, the cells were infected with one of the three KIR2DL2-associated
variants (Vpu-71/74, Gag-138 or Nef-9), or with wild-type virus, for 2 days. The
cells were then collected and stained with 2ml of the KIR2DL2-IgG or KIR2DL3-
IgG for 1 h on ice. The cells were then washed and stained with a secondary
allophycocyanin (APC)-conjugated goat anti-human IgG antibody for an addi-
tional 20min on ice. In parallel, infected cells were stained with the anti-human
antibody alone to define the background level of staining. All cells were then fixed
with 100ml of Fix A solution (Invitrogen) for 10min, washed and permeabilized
using 100ml of Perm B (Invitrogen). The cells were then stained for intracellular
p24 using the KC-57-RD1 antibody for 20min on ice, and then washed. Cells were
fixed in 1% paraformaldehyde until flow cytometric analysis was performed
(FACSCalibur; BD Biosciences).
HLA class I stabilization assays.HLA-C stabilization was assessed in 23 105 T2
cells that were incubated with 0.04mgml21 peptide, as indicated, overnight at
26 uC. The following day, peptide-pulsed T2 cells were stained with W632-PE
(eBioscience) antibody (HLA-A/B/C) or DT9 antibody (HLA-C/E) for 30min
at 4 uC. Cells were then washed in PBS before staining with anti-mouse IgG-PE
(Sigma) for 30min at 4 uC. Cells were washed twice with PBS and fixed in Perm A
solution (BD Biosciences). KIR2DL2–IgG binding to peptide-pulsed T2 cells was
assessed as previously described24.
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Supplemental Figure 1
Supplemental Figure 1: Distribution of KIR associated polymorphisms across the viral genome. The 
figure depicts the distribution of KIR –associated polymorphisms across the HIV genome. The bulk of the 
mutations cluster within variable genes that are expressed early during the viral life-cycle. Numbers correspond 
to numbers in Table 1.
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Supplemental Figure 2: Replication of the different viral constructs in CD4+ T cells in the absence of NK
cells. No differences in the replication capacity were observed among the wildtype (WT) and variant (V) viruses.
W W W. N A T U R E . C O M / N A T U R E  |  3
SUPPLEMENTARY INFORMATION RESEARCH
HIV p24+
2D
L2
-f
us
io
n 
co
ns
tr
uc
t
2o alone V/VWT/WT
C2
/C
2
C1
/C
2
C1
/C
1
Supplemental Figure 3
A B
** ** ** 
Supplemental Figure 3: Amino acid polymorphisms at 
positions 71/74 in VPU inhibit KIR2DL2 binding in an HLA-
C1 dependent manner. To determine whether a particular 
subgroup of HLA-C (KIR2DL2 ligands) was associated with 
differential KIR2DL2 mediated recognition of the viral 
polymorphisms, differences in the capacity of KIR2DL2 to 
interact with CD4+ T cells infected with the mutant or wild-type 
virus was compared using a KIR2DL2-IgG fusion construct. 
HIV-1-infected CD4+ T cells isolated from donors encoding for 
HLA-C group 1/1, 2/2, or 1/2 were stained. Significantly stronger 
binding to C1/C1+ than to C2/C2+ CD4+ T cells infected with 
the variant virus was observed. ** p < 0.005.
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Supplemental Figure 4
Supplemental Figure 4: Stabilization of HLA-Cw*0102-
expression on T2 cells by Vpu peptides and KIR2DL2
binding. T2 cells (HLA-A1, -B51 and –Cw*0102) were incubated
overnight at 26C with 0.04mg/ml of the HLA-Cw*0102-restricted
epitope peptides VAPWNSDAL or VAPWNSFAL24, or with the
peptides spanning the wild-type and variant sequences in Vpu
(Vpu MH: SALVEMGVEMGHHAPWD; Vpu RL:
SALVEMGVERGHLAPWD). HLA class I stabilization was
assessed by staining with a) W632 (binding to HLA-A,-B,-C) (n=5)
or b) DT9 (binding to HLA-C,-E) (n=5). Fold increase in MFI
relative to MFI of T2 cells in the absence of peptide is shown. C)
Flow cytometry histogram plots of the binding of isotype control
(KIR3DS1-Fc) or KIR2DL2-Fc (dotted line) in the presence of the
indicated peptides. In addition, overlapping 9-mer and 10-mer
peptides spanning the entire Vpu region were tested, however
none of those peptides resulted in KIR2DL2-binding (data not
shown).
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Supplemental Table 1. HLA class I and KIR typing of HIV-infected subjects
Subject A1 A2 B1 B2 Cw1 Cw2 2DL1 2DL2 2DL3 2DL4 2DL5 2DS1 2DS2 2DS3 2DS5 3DL1 3DS1 3DL2 3DL3
1 '0101 '0201 '3701 '5101 '0602 '1602 '0 '1 '0 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
2 '0201 '2402 '0720 '4402 '0501 '0702 '1 '1 '0 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1
3 '3002 '3303 '4403 '4403 '0304 '0401 '1 '1 '0 '1 '1 '0 '1 '1 '1 '1 '0 '1 '1
4 '0201 '2601 '3801 '4402 '0501 '1203 '1 '1 '0 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
5 '0101 '2902 '1510 '3910 '0401 '1203 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1 '0 '1 '1
6 '0101 '0301 '1402 '5701 '0602 '0802 '1 '1 '0 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1
7 '0301 '2601 '0702 '4402 '0501 '0702 '0 '1 '0 '1 '1 '1 '1 '0 '1 '0 '1 '1 '1
8 0201 2402 1801 5501 0303 0701 '1 '1 '0 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
9 '0101 '1101 '3501 '2705 0202 '0401 '1 '1 '0 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1
10 0101 0201 0801 4402 0501 0701 '1 '1 '0 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
11 '1101 '2402 '1402 '5501 '0304 '0802 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
12 '2301 '7400 '0801 '1402 '0701 '0802 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
13 0201 1101 1501 4402 0303 0501 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
14 '2402 '3201 '0705 '1302 '0602 '1505 '1 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1
15 '2601 '2902 '4403 '4901 '0701 '1601 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
16 '2902 '6801 '4002 '5201 '0202 '1505 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
17 2601 7401 3701 4901 0602 0701 '1 '1 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
18 '0201 '3101 '5101 '5101 '0102 '0401 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
19 2402 3012 3503 5703 0701 1203 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
20 '7401 '8001 '1801 '5703 '0202 '0701 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
21 '0101 '6801 '0801 '5702 '0701 '1800 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
22 0201 3201 4402 5101 0501 1502 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '1
23 '0201 '3002 '1503 '5101 '0210 '1602 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
24 '0101 '2601 '2705 '5601 '0102 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
25 '3303 '7401 '1503 '5801 '0202 '0701 '1 '1 '1 '1 '1 '0 '0 '0 '1 '1 '0 '1 '1
26 2902 6802 4403 5802 1601 0602 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
27 '1101 '6801 '1501 '1803 '0303 '0701 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
28 2402 8001 2705 5301 0202 0401 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
29 '0201 '3303 '0705 '4403 '0303 '1505 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
30 0205 2902 1402 5801 0701 0802 '1 '1 '1 '1 '1 '1 '1 0 '1 '1 '1 '1 '1
31 0201 0301 1501 3501 0303 0401 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
32 '0101 '0101 '0801 '5701 '0602 '0701 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
33 '0202 '6801 '1401 '1401 '0210 '0804 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
34 '0301 '3002 '0702 '1801 '0501 '0702 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
35 0201 6801 0702 4402 0702 0704 '1 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1
36 0101 1101 3501 5501 1402 0303 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '1
37 '2301 '6801 '1402 '5802 '0602 '0802 '1 '1 '1 '1 '1 '0 '0 '0 '1 '1 '0 '1 '1
38 '2301 '3402 '4403 '8101 '0401 '1801 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
39 6801 6802 0702 0801 0702 0701 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
40 '1101 '6801 '4402 '5802 '0501 '0602 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1 '1
41 0101 0201 2705 3701 0602 1203 '1 '1 '1 '1 '1 '0 '1 '0 '1 '1 '0 '1 '1
42 '0201 '3101 '0702 '1531 '0407 '0702 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
43 0201 3402 3501 4501 0401 1601 '1 '1 '1 '1 '1 '0 '1 '1 '0 '1 '0 '1 '1
44 '2301 '2601 '0702 '5301 '0602 '0702 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
45 '0201 '3002 '1801 '0801 '0501 '20 '1 '1 '1 '1 '0 '0 '1 '0 '0 '1 '0 '1 '1
46 '0202 '3012 '5301 '5801 '0802 '0401 '1 '1 '1 '1 0 0 '1 0 0 '1 0 '1 '1
47 0201 3601 5301 2705 0102 0401 '1 '1 '1 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
48 '0202 '3002 '4901 '7801 '0701 '1601 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
49 '0301 '2501 '1501 '4001 '0304 '0304 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
50 '0101 '0301 '0702 '0702 '0702 '0702 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
51 '2402 '6801 '0702 '1302 '0702 '0802 '1 '0 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1
52 '0301 '3002 '1801 '0801 '0501 '0702 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
53 0202 2902 0702 4901 0701 0701 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
54 '0101 '3201 '0801 '1801 '0701 '0701 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
55 '0101 '0301 '0702 '3508 '0401 '0702 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '0 '1 '1
56 1101 3201 0702 3503 0702 1202 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
57 '0201 '2601 '0801 '4402 '0501 '0702 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
58 0201 0301 4001 5101 0102 0304 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
59 '0301 '1101 '0702 '3901 '0702 '1203 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
60 '0301 '6802 '1510 '3501 0304 '0401 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
61 '2902 '3101 '3512 '4002 '0202 '0401 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
62 '2301 '2902 '4403 '4403 '1601 '1601 '1 '0 '1 '1 '1 '0 '0 '1 '0 '1 '0 '1 '1
63 '0101 '0201 '1801 '2705 '0202 '1203 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
64 '0101 '0201 '0702 '3512 '0401 '0702 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
65 '0101 '1101 '0801 '3504 '0401 '0701 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '1 '1 '1
66 '2402 '3201 '1502 '5101 '0801 '1602 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
67 '0101 '2402 '0801 '1801 '0701 '1203 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '1 '1 '1
68 '0201 '2301 '4501 '4501 '0602 '0602 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '1 '1 '1
69 0101 0101 1402 4403 0501 1601 '1 '0 '1 '1 '1 '1 '0 '1 '1 '1 '1 '1 '1
70 '1101 '2501 '3501 '3901 '0401 '1203 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '1 '1 '1
71 '0101 '3001 '0702 '4201 '1505 '1700 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
72 '0201 '0301 '1801 '4403 '0701 '1602 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
73 '0101 '0201 '0801 '5101 '0701 '1502 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
74 33 68 1510 5301 0304 0401 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '1 '1 '1
75 '0301 '2301 '0702 '4501 '0602 '0702 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
76 '2902 '6801 '4002 '5201 '0202 '1502 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
77 0217 2601 0801 4002 0305 0701 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
78 '0217 '2601 '0801 '4002 '0305 '0701 '1 '0 '1 '1 '1 '1 '0 '0 '1 '1 '1 '1 '1
79 '0201 '0204 '4402 '5101 '0501 '1502 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
80 '3601 '6802 '1510 '1516 '0304 '1402 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
81 0201 6801 1501 5501 0303 0501 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
82 '0301 '2423 '3501 '5101 '0401 '1402 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
83 '0204 '0205 '5101 5301 '0401 '1502 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
84 '0201 '0202 '3501 '4501 '1402 '1601 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
85 '0101 '0201 '5101 '5703 '1601 '0701 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
86 '0301 '3601 '4402 '0401 '0501 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
87 '0301 '6802 '4403 '5301 '0401 '0401 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
88 '0201 '0301 '3502 '4402 '0401 '0704 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
89 '0201 '0301 '3901 '0702 '0701 '0702 '1 '0 '1 '1 '0 0 '0 '0 '0 '1 '0 '1 '1
90 '0201 '1101 '3503 '4001 '0304 '0401 '1 '0 '1 '1 '0 0 '0 '0 '0 '1 '0 '1 '1
91 0101 6802 1510 5802 0304 0602 '1 '0 '1 '1 '0 '0 '0 '0 '0 '1 '0 '1 '1
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Suppl. Table 2. Vpu alignments
E M G H H A P W D V D
1 . . . . . . . . . I .
2 . L . . D . . . . I N
3 . . . . L . . . . . N
4 . . . . . . . . . . .
5 . . . . . . . . . I .
6 . . . . . . . . . I .
7 . R . . L . . . . . .
8 . . . R L V . R N . .
9 . . . . . . . . . . A
10 P . . N . . . . . . .
11 . . . . D . . . V I .
12 . . . . . . . . . I N
13 D . . . . . . . . . N
14 . . . . . . . . . . N
15 D . . . . . . . . . N
16 . . . . . . . . . . .
17 . . . . D . . . . . N
18 . . . . . . . . . . .
19 . . . . D . . . V . N
20 . . . . . . . G . I N
21 . . . . . . . . . I .
22 A . . . . . . . . I .
23 . . . . D . . . . . N
24 . . . . . . . . P I .
25 . . . . . . . . . I N
26 . . . . . . . . . I .
27 . . . . . . . . . I .
28 . . . . . . . . . . N
29 . . . . . . . . . . N
30 . R . . L T . . . I .
31 . . . . . . . . . . .
32 . . . . L I . G A I N
33 - - - . . . . - . . .
34 . . . . . . . . . . .
35 . . . . . . . . . . A
36 H Q A . . . . . . I .
37 . . . . . . . . . . N
38 . . . . . . . . . . N
39 . . . . . . . . N . N
40 . . . . . . . . . . N
41 . . . . . . . . N . .
42 . . . . . . . . V . .
43 . . . . . . . . . . N
44 . . . . . . . . N . .
45 . . . . D . . . . . .
46 P . . . . . . . . . N
47 D . . P . D L . N I N
48 . . . . R . . G . I N
49 . . . . . . . . . I .
50 . . . . . . . . . I .
51 D . . . . . . . . . .
52 . V . . . . . . . . .
53 . R . . L . . . . . N
54 . R . . L . . . . I .
55 . . . . . . . . . . N
56 . R . . L . . . N I .
57 . . . R L . . . . I N
58 . . . . . . . . . . N
59 . . . Y . . . . . I .
60 . . . . . . . . . . N
61 . R . . L . . . . . .
62 . R . . L . . . . . N
63 . R . . L . . . . . N
64 . . . . . . . . . . N
65 . R . . L . . . . I .
66 . R . . L . . . . . N
67 . . . . D . . . . . .
68 . . . . D . . . . . .
69 . R . . L . . . N I .
70 . . . . . . . . . . N
71 H Q A . D . . . . . .
72 . . . . L . . . . I .
73 . R . . . . . . . . .
74 . R . . L . . . . I N
75 H N A . . . . . . I .
76 . . . . D . L . V . N
77 . . . . L . L G . . N
78 . R . . L . . . . . N
79 . R . . L . . . . . N
80 . . . . . . . . . I .
81 . R . . L . . . N . .
82 . . . . D . . . . . N
83 . R . . L . . . . . N
84 . . . . . D . G . . .
85 . R . . L . . R . I .
86 D . E Q . . L L L I .
87 . . . . . . . . . . N
88 . . . . L . . . . . N
89 . . . . L . . . . . .
90 M G . . D . . . . . N
91 . . . . . . . . . . N
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Suppl. Table 3. Env Alignments
W R W G T M L L G M L
1 . K . . I . . . . T .
2 . S . . . . . . . I .
3 . . . . I L . . . . .
4 . . . . I T . . . . .
5 . . . . I . . . . I .
6 . . . . . . . . . T .
7 . K G . I L . . . . .
8 . . . . A L F . . . .
9 . . . . I . . . . . .
10 L . . . . . . . . . .
11 . . . . M . . . . L .
12 . . . . . . . . . I .
13 G I . . . . . . . . .
14 . K . . I . . . . . .
15 G I . . . . . . . . .
16 . . . . . . . . . . .
17 . . . . M . . . . . .
18 . K . . . . . . . . .
19 . . . . . . . . . L .
20 . . . . I . . . E I .
21 . K . . . . . . . I .
22 . . . . . . . . . I .
23 . K . . M . . . . . .
24 . . . . . . . . . L .
25 . . . . . . . . . I .
26 . K . . I . . . . T .
27 . . . . . . . . . I .
28 . K . . . . . . . . .
29 . K . . I . . . . . .
30 . K G . I L . . . I .
31 . . . . I . . . . . .
32 G . . . I L F . . L .
33 . . . . . . . . . . .
34 . K . . . . . . . . .
35 . . . . I . . . . . .
36 G T R L . . . . . I .
37 . . . . . . . . . . .
38 . . . . I . . . . . .
39 . . . . I . . . . . .
40 . . . . I . . . . . .
41 . . . . . . . . . . .
42 . . . . I . . . . L .
43 . K . . . . . . . . .
44 . . . . I . . . . . .
45 . . . . M . . . . . .
46 L Q . . . . . . . . .
47 . T . . L . I F . I .
48 . . . . . V . . . I .
49 . . . . . . . . . I .
50 . K . . . . . . . I .
51 R T . . . . . . . . .
52 . . . . . . . . . . .
53 . K G . . L . . . . .
54 . . G . . L . . . I .
55 . . . . . . . . . . .
56 . . G . . L . . . I .
57 . . . . V L . . . I .
58 . K . . I . . . . . .
59 . K . . I . . . . I .
60 . . . . I . . . . . .
61 . . G . . L . . . . .
62 . . G . . L . . . . .
63 . . G . . L . . . . .
64 . . . . I . . . . . .
65 . K G . I L . . . I .
66 . . G . . L . . . . .
67 . K . . . . . . . . .
68 . . . . M . . . . . .
69 . . G . . L . . . I .
70 . . . . I . . . . . .
71 G T R L M . . . . . .
72 . . . . I L . . . I .
73 . . G . . . . . . . .
74 . . G . I L . . . I .
75 G T M L . . . . . I .
76 . . . . M . . F . L .
77 . K . . . L . . . . .
78 . . G . . L . . . . .
79 . K G . I L . . . . .
80 . K . . I . . . . I .
81 . . G . I L . . . . .
82 . K . . . . . . . . .
83 . K G . I L . . . . .
84 . . . . . . I . . . .
85 . K G . I L . . . I .
86 . T . S S . . F C L .
87 . . . . . . . . . . .
88 . . . . I L . . . . .
89 . . . . I L . . . . .
90 K W G . M . . . . . .
91 . . . . . . . . . . .
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Suppl. Table 4. Nef Alignments
K W S K R S V V G W P
1 . . . . . . I . . . .
2 . . . . N . I . . . .
3 . . . . S . . T . . .
4 . . . . S . I . . . .
5 . . . . . . E P . . F
6 . . . . P . F P . . A
7 . . . . S . . . . . .
8 N . . . . . M P . . S
9 . . . . - E - - . . .
10 G . A A . E R M Q R A
11 . . . . S . . . . . S
12 . . . . S . . . . . .
13 . . . . S . . . . . .
14 . . . . P R . P . . S
15 . . . . S . . . . . .
16 . . . . . . M G . . S
17 . . . . S . . . . . .
18 . . . . - N M C . . .
19 . . . . S . . . . . .
20 . . . . . . E N . . S
21 . . . . - C M S . . .
22 . . . . S . K . . . .
23 . . . . S . L . . . .
24 . . . . . . M G . . S
25 . . . . S . I . . . .
26 . . . . . . . P . . T
27 . . . . . . R D . . S
28 . . . . S . . . . . S
29 . . . . . . . P . . S
30 . L . . . - M R . . A
31 . . . . S . M G . . S
32 . . . . . . A P . . S
33 . . . . - - L S . . N
34 . . . . . K E N . . S
35 . . . . E . K E E . .
36 . C . . . - M P . . .
37 . L . . . . A P . . S
38 . - G S K L S K . . Q
39 . - G S K L S K . . Q
40 . C . . . . - . E . N
41 . . . . - . I . . . .
42 . . . . C . P I . . .
43 S
44 . . . . M . - - . . .
45 . . . . - C - S . . .
46 . . . . . . M S . . .
47 . . . . S . I . . . .
48 . . . . . . G . . . .
49 . . . . S K I F . . S
50 . . . . S . . I . . .
51 . . . . S . . . . . .
52 . . . . S . . . . . .
53 . . . . S K M F . . S
54 . . . . . - M A . . .
55 . . . . S . . . . . .
56 . . . . . . . P . . .
57 . . . . . . G G . . E
58 . . . . C . L . . . .
59 . . . . H P G S . . A
60 . . . . . . . T E . .
61 . . . . S K . A . . S
62 . . . . S K M G . . S
63 . . . . S . I . . . .
64 . . . . S R G F . . Q
65 . . . . . - L G . . .
66 . . . . S K M G . . S
67 . . . . S . M A K . .
68 . . . . . . L G . . .
69 . . . R S I G A . . S
70 . . . . . . R D . . Q
71 . . . . N K I . D . .
72 . . . . S I G S . . S
73 . . . . S . K I . . .
74 . . . . Y . - - . . A
75 . C . . . - M P . . .
76 . . . . G G L G K . .
77 . . . . S W P A V R E
78 . . . . - - F S . . A
79 . . . . . K A E . . S
80 . . . . S . . . . . A
81 . . . . . . - - Q . S
82 . . . . - . K L . . .
83 . . . . - - F C . . .
84 . . . . . G . P . . .
85 . . . . . . N K D . .
86 . . . . . . . P . . .
87 . . . . . K R D . . S
88 . . . . S . . . . . .
89 . . . . . . K I . . .
90 . . . . S . . . . . .
91 . . . . N K I P . . .
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Suppl. Table 5. Gag Alignments
P I V Q N L Q G Q M V
1 . . . . . M . . . . .
2 . . . . . . . . . . .
3 . . . . . . . . . . .
4 . . . . . . . . . . .
5 . . . . . . . . . . .
6 . . . . . M . . . . I
7 . . . . . . . . . . .
8 . . . . . M . . . . .
9 . . . . . . . . . . .
10 . . . . . . . . . . .
11 . . . . . . . . . . .
12 . . . . . . . . . . .
13 . . . . . . . . . . .
14 . . I . . . . . . . .
15 . . . . . . . . . . .
16 . . . . . . . . . . .
17 . . . . . M . . . . .
18 . . . . . . . . . . .
19 . . . . . . . . . . .
20 . . . . . . . . . . .
21 . . . . . . . . . . .
22 . V . . . M . . . . .
23 . . . . . . . . . . .
24 . V . . . . . . . . .
25 . . . . . M . . . . .
26 . . . . . M . . . . .
27 . . . . . . . . . . .
28 . . . . . M . . . . .
29 . . . . . . . . . . .
30 . . . . . . . . . . .
31 . . . . . M . . . . .
32 . . . . . M . . . . .
33 . . . . . . . . . . .
34 . . . . . M . . . . .
35 . . . . . . . . . . .
36 . . . . . . . . . . .
37 . . . . . V . . . . .
38 . . . . . . . . . . .
39 . . . . . . . . . . .
40 . . . . . . . . . . .
41 . . . . . . . . . . .
42 . . . . . . . . . . .
43 . . . . . M . . . . .
44 . . . . . . . . . . .
45 . . . . . V . . . . .
46 . . . . . . . . . . .
47 . . . . . A . . . . .
48 . . . . . I . . . . .
49 . . . . . M . . . . .
50 . . . . . . . . . . .
51 . . . . . . . . . . .
52 . . . . . . . . . . .
53 . . . . . M . . . . .
54 . . . . . . . . . . .
55 . . . . . . . . . . .
56 . . . . . . . . . . .
57 . . . . . . . . . . .
58 . . . . . I . . . . .
59 . . . . . V . . . . .
60 . . . . . I . . . . .
61 . . . . . M . . . . .
62 . . . . . . . . . . .
63 . . . . . M . . . . .
64 . . . . . . . . . . .
65 . . . . . M . . . . .
66 . . . . . . . . . . .
67 . . . . . A . . . . .
68 . . . . . I . . . . .
69 . . . . . . . . . . .
70 . . . . . M . . . . .
71 . . . . . . . . . . .
72 . . . . . I . . . . .
73 . . . R . . . . . . .
74 . . . . . . . . . . .
75 . . . . . . . . . . .
76 . . . . . . . . . . .
77 . . . . . . . . . . .
78 . . . . . M . . . . .
79 . . . . . . . . . H .
80 . . . . . . . . . . .
81 . . . . . . . . . . .
82 . . . . . I . . . . .
83 . . . . . . . . . . .
84 . . . . . . . . . . .
85 . . . . . . . . . . .
86 . . . . . . . . . . .
87 . . . . . I . . . . .
88 . . . . . M . . . . .
89 . . . . . I . . . . .
90 . . . . . A . . . . .
91 . . . . . . . . . . .
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Supplemental Table 6. KIR and HLA class I genotypes of Healthy Donors
2DL1 2DL2 2DL3 2DL4 2DL5 2DS1 2DS2 2DS3 2DS5 3DL1 3DS1 3DL2 3DL3 HLA-A1 HLA-A2 HLA-B1 HLA-B2 HLA-C1 HLA-C2
A 1 1 1 1 0 0 1 0 0 1 0 1 1 0301 6802 0702 1402 0702 0802 C1 C1
B 1 1 1 1 0 0 1 0 0 1 0 1 1 0201 0201 1801 3901 0501 1203 C2 C1
C 1 1 1 1 1 0 1 1 0 1 0 1 1 0201 2402 3502 3931 0401 1203 C2 C1
D 1 1 1 1 0 0 1 0 0 1 0 1 1 0301 2402 0702 3906 0702 0702 C1 C1
E 1 1 1 1 1 0 1 1 0 1 0 1 1 0301 3201 0702 5001 0602 0702 C2 C1
F 1 1 1 1 0 0 1 0 0 1 0 1 1 2902 6802 1402 2705 0202 0804 C2 C1
G 1 1 1 1 0 0 1 0 0 1 0 1 1 0301 3004 1801 5108 1203 1602 C1 C2
H 1 1 1 1 1 0 1 1 0 1 0 1 1 0205 6801 3503 4901 0401 0701 C2 C1
I 1 1 1 1 0 0 1 0 0 1 0 1 1 0101 0201 0702 4102 0602 0701 C2 C1
J 1 1 1 1 1 1 1 0 1 1 0 1 1 0201 0302 3508 5201 0401 1202 C2 C1
K 1 1 1 1 1 0 1 1 0 1 0 1 1 0101 1101 3501 3701 0401 0701 C2 C1
L 1 1 1 1 0 0 1 0 0 1 0 1 1 2902 3101 4402 4501 0602 0704 C2 C1
M 1 1 0 1 1 1 1 1 0 1 0 1 1 0201 0201 0702 4102 1203 1602 C1 C2
N 1 1 1 1 0 0 1 0 0 1 0 1 1 2601 3101 2705 4901 0102 0701 C1 C1
O 1 1 1 1 1 1 1 0 1 1 0 1 1 0101 2402 3501 3501 0401 0701 C2 C1
P 1 0 1 1 0 0 0 0 0 1 0 1 1 0101 0201 0801 3501 0401 0701 C2 C1
Q 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 2601 1501 2705 0102 0303 C1 C1
R 1 0 1 1 0 0 0 0 0 1 0 1 1 2501 3101 1401 1801 0802 1203 C1 C1
S 1 0 1 1 0 0 0 0 0 1 0 1 1 0205 2601 3801 5001 0602 1203 C2 C1
T 1 0 1 1 0 0 0 0 0 1 0 1 1 0301 3201 0801 3508 0401 0701 C2 C1
U 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 1101 1501 3501 0303 0401 C1 C2
V 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 0206 4011 4402 0304 0501 C1 C2
W 1 0 1 1 0 0 0 0 0 1 0 1 1 1101 2402 1301 1525 0304 0403 C1 C2
X 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 0206 4011 4402 0304 0501 C1 C2
Y 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 3303 1501 5801 0302 0801 C1 C1
Z 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 0201 0702 5601 0102 0702 C1 C1
AA 1 0 1 1 0 0 0 0 0 1 0 1 1 0101 0301 0702 1501 0304 0702 C1 C1
AB 1 0 1 1 0 0 0 0 0 1 0 1 1 0201 3002 0702 2705 0102 0702 C1 C1
AC 1 0 1 1 0 0 0 0 0 1 0 1 1 0101 2601 0702 0801 0701 0702 C1 C1
AD 1 0 1 1 0 0 0 0 0 1 0 1 1 0101 0201 1801 5101 0602 1402 C2 C1
C group
